BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

979 related articles for article (PubMed ID: 25348937)

  • 1. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer.
    Sugie T; Sawada T; Tagaya N; Kinoshita T; Yamagami K; Suwa H; Ikeda T; Yoshimura K; Niimi M; Shimizu A; Toi M
    Ann Surg Oncol; 2013 Jul; 20(7):2213-8. PubMed ID: 23429938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence.
    Murawa D; Hirche C; Dresel S; Hünerbein M
    Br J Surg; 2009 Nov; 96(11):1289-94. PubMed ID: 19847873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer.
    Hirche C; Murawa D; Mohr Z; Kneif S; Hünerbein M
    Breast Cancer Res Treat; 2010 Jun; 121(2):373-8. PubMed ID: 20140704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE;
    Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients.
    Hirano A; Kamimura M; Ogura K; Kim N; Hattori A; Setoguchi Y; Okubo F; Inoue H; Miyamoto R; Kinoshita J; Fujibayashi M; Shimizu T
    Ann Surg Oncol; 2012 Dec; 19(13):4112-6. PubMed ID: 22782671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting axillary sentinel node status in patients with primary breast cancer.
    Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
    Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer.
    Hirche C; Mohr Z; Kneif S; Murawa D; Hünerbein M
    J Surg Oncol; 2012 Feb; 105(2):162-6. PubMed ID: 21882198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer.
    Hojo T; Nagao T; Kikuyama M; Akashi S; Kinoshita T
    Breast; 2010 Jun; 19(3):210-3. PubMed ID: 20153649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients.
    van der Vorst JR; Schaafsma BE; Verbeek FP; Hutteman M; Mieog JS; Lowik CW; Liefers GJ; Frangioni JV; van de Velde CJ; Vahrmeijer AL
    Ann Surg Oncol; 2012 Dec; 19(13):4104-11. PubMed ID: 22752379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer.
    Wishart GC; Loh SW; Jones L; Benson JR
    Eur J Surg Oncol; 2012 Aug; 38(8):651-6. PubMed ID: 22704050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary recurrence after sentinel lymph node biopsy.
    van der Vegt B; Doting MH; Jager PL; Wesseling J; de Vries J
    Eur J Surg Oncol; 2004 Sep; 30(7):715-20. PubMed ID: 15296984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy in male breast cancer patients.
    Goyal A; Horgan K; Kissin M; Yiangou C; Sibbering M; Lansdown M; Newcombe RG; Mansel RE; Chetty U; Ell P; Fallowfield L; Kissin M;
    Eur J Surg Oncol; 2004 Jun; 30(5):480-3. PubMed ID: 15135473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.
    Mustać E; Matusan-Ilijas K; Marijić B; Smokvina M; Jonjić N
    Int J Surg Pathol; 2010 Feb; 18(1):36-41. PubMed ID: 19448065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dye- and gamma probe-guided sentinel lymph node biopsy in breast cancer patients: using patent blue dye and technetium-99m-labeled human serum albumin.
    Tsugawa K; Noguchi M; Miwa K; Bando E; Yokoyama K; Nakajima K; Michigishi T; Tonami N; Minato H; Nonomura A
    Breast Cancer; 2000 Jan; 7(1):87-94. PubMed ID: 11029778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green.
    Aoyama K; Kamio T; Ohchi T; Nishizawa M; Kameoka S
    World J Surg Oncol; 2011 Dec; 9():157. PubMed ID: 22132943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.